Drug profile: Transdermal rivastigmine patch in the treatment of alzheimer disease

CNS Neuroscience and Therapeutics

Volumn 16, Issue 4, 2010, Pages 246-253

  Emre, Murat ^a   Bernabei, Roberto ^b   Blesa, Rafael ^c   Bullock, Roger ^d   Cunha, Luis ^e   Daniëls, Hugo ^f   Dziadulewicz, Edward ^g   Förstl, Hans ^h   Frölich, Lutz ⁱ   Gabryelewicz, Tomasz ^j   Levin, Oleg ^k   Lindesay, James ^l   Martínez Lage, Pablo ^m   Monsch, Andreas ⁿ   Tsolaki, Magda ^o   Van Laar, Teus ^p  

^a ISTANBUL UNIVERSITY   (Turkey)

^b CATHOLIC UNIVERSITY   (Italy)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d Kingshill Research Centre   (United Kingdom)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f DEPARTMENT OF CARDIOLOGY   (Belgium)

^g Novartis Pharmaceuticals UK Limited   (United Kingdom)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^k Russian Postgraduate Medical Academy   (Russian Federation)

^l UNIVERSITY OF LEICESTER   (United Kingdom)

^m Fundación Alzheimer Centre Educational   (Spain)

ⁿ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^o ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^p UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

Alzheimer's disease; Patch; Rivastigmine; Transdermal; Treatment

Indexed keywords

ACETYLCHOLINESTERASE; CORTICOSTEROID; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OUTCOME ASSESSMENT; REVIEW; SIDE EFFECT; SKIN ALLERGY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; VOMITING; WEIGHT REDUCTION; ANIMAL; INTRADERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; PHENYLCARBAMATES;

EID: 77954353128     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00141.x     Document Type: Review

References (38)

1. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: Potential benefits of a transdermal patch. Curr Med Res Opin 2007 23 : 2705 2713.
2. Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: What doctors believe and patients actually do. Br J Clin Pharmacol 2001 51 : 615 622.
3. Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999 12 : 307 323.
4. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999 318 : 633 638.
5. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998 1 : 55 65.
6. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004 351 : 2509 2518.
7. Feldman HH, Lane R. Rivastigmine: A placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007 78 : 1056 1063.
8. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol 1998 1 (suppl 1 S26 S34.
9. Winblad B, Machado JC. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008 5 : 1377 1386.
10. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 22 : 456 467.
11. Jhee SS, Shiovitz T, Hartman RD, et al. Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. Clin Neuropharmacol 2002 25 : 122 123.
12. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002 127 : 45 63.
13. Darvesh S, Walsh R, Kumar R, et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 2003 17 : 117 126.
14. Spencer CM, Noble S, Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 1998 13 : 391 411. (Pubitemid 28523796)
15. Bellelli G, Lucchi E, Minicuci N, et al. Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): A 36-week follow-up study. Aging Clin Exp Res 2005 17 : 54 61.
16. Lefèvre G, Sdek G, Jhee S, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008 83 : 106 114.
17. Mercier F, Lefèvre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007 23 : 3199 3204.
18. Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother 2007 7 : 1457 1463. (Pubitemid 350106826)
19. Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2000 2 : 68 72.
20. Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit. J Neural Transm 2002 109 : 1053 1065.
21. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002 59 : 563 572.
22. Lefèvre G, Sdek G, Huang HL, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: Relative effects of body site application. J Clin Pharmacol 2007 47 : 471 478.
23. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review. Int J Clin Pract 2009 63 : 799 805.
24. Grossberg G, Sadowsky C, Förstl H, et al. Safety and tolerability of the rivastigmine patch: Results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009 23 : 158 164.
25. Sadowsky CH, Dengiz A, Olin JT, et al. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2009 24 : 267 275.
26. Rivastigmine (Exelon®). Summary of product characteristics. Available from : http://www.emea.europa.eu/humandocs/PDFs/EPAR/Exelon/H-169-PI-en.pdf Assessed July 15 2009 MW, Adler G, Ibach B, et al. Adding memantine to rivastigmine therapy in patients with mild-to-moderate Alzheimer's disease: Results of a 12-week, open-label pilot study. Prim Care Companion J Clin Psychiatry 2006 8 : 258 263.
27. Shua-Haim J, Smith J, Picard F, et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: An open-label, crossover, single-centre study. Clin Drug Investig 2008 28 : 361 374.
28. Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: A 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2009 [Epub ahead of print]. doi :.
29. Ale I, Lachapelle J-M, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: An overview. Adv Ther 2009 26 : 920 935.
30. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007 22 : 485 491.
31. Fitzpatrick AL, Kuller LH, Lopez OL, et al. Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci 2005 229-230 : 43 49.
32. Singh G, Thomas SK, Arcona S, et al. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc 2005 53 : 1269 1270.
33. Sicras-Mainar A, Vergara J, Leon-Colombo T, Febrer L, Rejas-Gutierrez J. Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine [In Spanish]. Rev Neurol 2006 43 : 449 453.
34. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastimgine or donepezil in usual care settings. J Manag Care Pharm 2005 11 : 231 239.
35. Small GW, Kaufer D, Mendiondo MS, et al. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005 59 : 473 477.
36. Becker M, Andel R, Rohrer L, Banks SM. The effect of cholinesterase inhibitors on risk of nursing home placement among medicaid beneficiaries with dementia. Alzheimer Dis Assoc Disord 2006 20 : 147 152.
37. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007 4 : 37 45.
38. Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: Impact on the elderly. Drugs Aging 2006 23 : 357 375.